Bladder cancer: open trials in China

167 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT07090499
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Trial Treatment · Phase 1 · Pfizer
Hunan Cancer Hospital, Changsha
Registry updated 2026-11-05
NCT07853053
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
Trial Treatment · Phase 1 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
Registry updated 2026-11-05
NCT05614739
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Trial Treatment · Phase 1 · Eli Lilly and Company
Beijing Cancer Hospital, Beijing · Beijing Hospital, Beijing · Sun Yat-Sen University Cancer Center, Guangdong · Zhejiang Provincial People's Hospital, Hangzhou · Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou · Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai · Tianjin Medical University Cancer Institute & Hospital, Tianjin · The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Registry updated 2026-11-04
NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Trial Treatment · Phase 1 · Eli Lilly and Company
Beijing Cancer Hospital, Beijing · Sun Yat-sen University Cancer Center, Guangzhou · Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Registry updated 2026-11-04
NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 2 · Bayer
Beijing Cancer Hospital - Oncology Department, Beijing · Peking University First Hospital - Oncology Department, Beijing · Hunan Cancer Hospital - Oncology Department, Changsha · Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department, Hangzhou · Zhongshan Hospital,Fudan University, Shanghai · Fudan University Shanghai Cancer Center - Oncology Department, Shanghai
Registry updated 2026-11-04
NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Peking University Third Hospital, Beijing · Beijing Friendship Hospital, Capital Medical University, Beijing · Hunan Cancer Hospital, Changsha · The Third People's Hospital of Chengdu, Chengdu · West China School of Medicine/West China Hospital, Sichuan University, Chengdu · Chongqing Cancer Hospital, Chongqing · Fujian Medical University Union Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · Zhongda Hospital Southeast University, Nanjing · Nanjing Drum Tower hospital, Nanjing · Huadong Hospital Affiliated to Fudan University, Shanghai · The Second Hospital of Tianjin Medical University, Tianjin · Cancer Hospital of Xinjiang Medical University, Ürümqi · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan · The First Affiliated Hospital of Xian Jiaotong University, Xinshi · The affiliated hospital of xuzhou medical university, Xuzhou
Registry updated 2026-11-03
NCT06919965
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Peking University First Hospital, Beijing · The Third People's Hospital of Chengdu, Chengdu · West China Hospital，Sichuan University, Chengdu · Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou · Nanjing Drum Tower hospital, Nanjing · The First Affiliated Hospital of Ningbo University, Ningbo · The Second Hospital of Tianjin Medical University, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology, Wuhan · Yantai Yuhuangding Hospital, Yantai
Registry updated 2026-11-03
NCT07187635
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
Trial Treatment · Tianjin Medical University Second Hospital
Sun Yat Sen Memorial Hospital of Sun Yat sen University, Guangzhou · The Second Affiliated Hospital of Kunming Medical University, Kunming · Nanchang Second People's Hospital, Nanchang · RenJi Hospital, Shanghai · General Hospital of Tianjin Medical University, Tianjin · The Second Hospital of Tianjin Medical University, Tianjin · Xingtai People's Hospital, Xingtai
Registry updated 2026-11-03
NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Peking University First Hospital ( Site 0184), Beijing · The Second Xiangya Hospital of Central South University ( Site 0916), Changsha · Hunan Cancer Hospital ( Site 0182), Changsha · West China Hospital of Sichuan University ( Site 0185), Chengdu · The First Affiliated Hospital of Chonqing Medical University ( Site 0197), Chongqing · Sun Yat-sen Memorial Hospital, Sun Yat-sen University-Urology Surgery ( Site 0189), Guangzhou · Zhujiang Hospital of Southern Medical University ( Site 0205), Guangzhou · Sun Yat-Sen University Cancer Center ( Site 0188), Guangzhou · Sun Yat-Sen University Cancer Center ( Site 0183), Guangzhou · The First Hospital of Jiaxing ( Site 0901), Jiaxing · Jiangxi Cancer Hospital ( Site 0192), Nanchang · Jiangsu Cancer Hospital ( Site 0917), Nanjing · The First Affiliated Hospital of Ningbo University ( Site 0193), Ningbo · Fudan University Shanghai Cancer Center ( Site 0181), Shanghai · Zhongshan Hospital Fudan University ( Site 0907), Shanghai · The Second Hospital of Tianjin Medical University ( Site 0910), Tianjin · Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0186), Wenzhou · The First Affiliated Hospital of Wenzhou Medical University ( Site 0194), Wenzhou · Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0198), Wuhan · The Fifth Affiliated Hospital of Sun Yat-Sen University ( Site 0900), Zhuhai
Registry updated 2026-11-03
NCT07646145
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
Trial Treatment · Phase 2 · Shanxi Province Cancer Hospital
Shanxi Provincial Cancer Hospital, Taiyuan
Registry updated 2026-11-03
NCT07475806
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Trial Treatment · Phase 2 · Astellas Pharma Global Development, Inc.
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing · Shanghai Tenth People's Hospital, Chengdu · Langfang Campus, Cancer Hospital Chinese Academy of Medical Science, Langfang · Sichuan Cancer Hospital, Shanghai
Registry updated 2026-11-02
NCT07720921
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
Trial Treatment · Phase 2 · Peking University First Hospital
Departmeng of Urology, Peking University First Hospita, Beijing
Registry updated 2026-10-28
NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Trial Treatment · Phase 2 · Daiichi Sankyo
West China Hospital，Sichuan University, Chengdu · Sun Yat-sen University Cancer Center, Guangzhou
Registry updated 2026-10-26
NCT07879469
Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Trial Treatment · Phase 2 · Tianjin Medical University Second Hospital
The Second Hospital of Tianjin Medical University, Tianjin · Xingtai People's Hospital, Xingtai
Registry updated 2026-10-23
NCT07888374
Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification
Research · Ruijin Hospital
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Registry updated 2026-10-22
NCT07625527
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Trial Treatment · Phase 2 · Tianjin Medical University Second Hospital
General Hospital of Tianjin Medical University, Tianjin · The Second Hospital of Tianjin Medical University, Tianjin · Tianjin Hospital, Tianjin · Xingtai People's Hospital, Xingtai
Registry updated 2026-10-15
NCT07875959
18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors
Trial Treatment · Peking University First Hospital
Peking University First Hospital, Beijing
Registry updated 2026-10-15
NCT03108196
Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder
Trial Treatment · Zhujiang Hospital
Zhujiang Hospital, Guangzhou
Registry updated 2026-10-09
NCT04861584
Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
Trial Treatment · Phase 2 · Zhujiang Hospital
Zhujiang Hospital, Guangzhou
Registry updated 2026-10-09
NCT05067101
Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men With Bladder Cancer
Trial Treatment · Zhujiang Hospital
Chunxiao Liu, Guangzhou
Registry updated 2026-10-09
NCT07749924
Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC
Trial Treatment · Tianjin Medical University Second Hospital
Daqing Oil General Hopital, Daqing · Nanchang Second People's Hospital, Nanchang · The Second Hospital of Tianjin Medical University, Tianjin · Tianjin Hospital, Tianjin · General Hospital of Tianjin Medical University, Tianjin
Registry updated 2026-10-09
NCT05558111
The Supraspinal Control of Lower Urinary Tract Function in Patients With Orthotopic Sigmoid Neobladder.
Research · Zhujiang Hospital
Zhujiang Hospital of Southern Medical University, Guangzhou
Registry updated 2026-10-08
NCT06341400
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
Trial Treatment · Phase 1/2 · Zhujiang Hospital
Zhujiang Hospital, Southern Medical University, Guangzhou
Registry updated 2026-10-08
NCT07421700
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Trial Treatment · Phase 1/2 · Pfizer
Beijing Cancer Hospital, Beijing · Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing · The First Affiliated Hospital of Ningbo University, Ningbo · The Second Hospital of Tianjin Medical University, Tianjin
Registry updated 2026-10-08
NCT07865611
Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer
Trial Treatment · Phase 2 · Tongji Hospital
Tongji Hospital, Wuhan
Registry updated 2026-10-08

All Bladder cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error